TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 751-757

  Sparano, Joseph A ^a   Goldstein, Lori J ^b   Davidson, Nancy E ^c   Sledge Jr , George W ^d   Gray, Robert ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

Breast cancer; Recurrence; TOP2A RNA expression

Indexed keywords

ESTROGEN RECEPTOR; RNA;

ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; TOPOISOMERASE 2 ALPHA GENE; TREND STUDY; VALIDATION STUDY;

ALGORITHMS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK FACTORS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84868193105     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2112-7     Document Type: Article

References (18)

1. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
2. Paik S, Tang G, Shak S, et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734
3. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728
4. Oratz R, Kim B, Chao C et al (2011) Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract 7:94-99
5. Lo SS, Mumby PB, Norton J et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676
6. Rody A, Karn T, Ruckhaberle E et al (2009) Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 113:457-466
7. Brase JC, Schmidt M, Fischbach T et al (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16:2391-2401
8. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375
9. Oakman C, Moretti E, Sotiriou C et al (2009) Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:1735-1936 author reply 1736-1737
10. Sparano JA, Goldstein LJ, Childs BH et al (2009) Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 15:7693-7700
11. Villman K, Stahl E, Liljegren G et al (2002) Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Modern Pathol 15:486-491
12. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679
13. van de Vijver MJ, He YD, van't Veer LJ (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
14. Desmedt C, Piette F, Loi S et al (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207-3214
15. Loi S, Haibe-Kains B, Desmedt C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246
16. Loi S, Haibe-Kains B, Desmedt C et al (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239
17. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184
18. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350